β³ Fetching live dividend data...
Home βΊ Calculator βΊ NKGN Dividend Calculator 2026
NKGen Biotech, Inc. Common Stock Β· OTC
Price: $0.06 Β· Annual div: $2.00/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in NKGN β $6.138874813290036e+26M in 10 years Β· $51,155,791,405,923,940,000,000,000,000,000.00/month
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company's autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open NKGN position with:
Real after-tax yield depends on where you live and how you hold NKGN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 3333.33% | 3330.53% | $333,333 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 2833.33% | 2830.53% | $283,333 / yr |
| πΊπΈ US Taxable (20%) | 20% | 2666.66% | 2663.86% | $266,666 / yr |
| π¬π§ UK ISA | 0% | 3333.33% | 3330.53% | $333,333 / yr |
| π¬π§ UK Taxable | 8.75% | 3041.66% | 3038.86% | $304,166 / yr |
| π¨π¦ TFSA | 0% | 3333.33% | 3330.53% | $333,333 / yr |
| π¨π¦ CA Taxable | 25% | 2500.00% | 2497.20% | $250,000 / yr |
| π¦πΊ Super (pension) | 15% | 2833.33% | 2830.53% | $283,333 / yr |
| π¦πΊ AU Taxable | 30% | 2333.33% | 2330.53% | $233,333 / yr |
| π©πͺ DE Taxable | 26.375% | 2454.16% | 2451.36% | $245,416 / yr |
| π«π· FR Taxable | 30% | 2333.33% | 2330.53% | $233,333 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
NKGN pays quarterly β 4 times per year. Next ex-div: TBD.
How NKGN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for NKGN sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2025-05-27 | 39,339,103 | $0.13 | $5.00M | ||
| Buy | 2025-05-27 | 19,669,552 | $0.13 | $2.50M | ||
| Buy | 2025-05-05 | 41,699,449 | $0.13 | $5.30M | ||
| Buy | 2025-05-05 | 20,849,725 | $0.13 | $2.65M | ||
| J-Other | 2024-12-20 | 63,634 | β | β | ||
| D-Return | 2024-12-20 | 757,942 | $11.50 | $8.72M | ||
| D-Return | 2024-12-20 | 93,334 | $11.50 | $1.07M | ||
| D-Return | 2024-12-02 | 713,357 | $11.50 | $8.20M | ||
| D-Return | 2024-12-16 | 1,212,707 | $11.50 | $13.95M | ||
| J-Other | 2024-12-02 | 97,232 | β | β |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the NKGN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review β